8-K: SS&C Technologies Reports Record Adjusted Revenue and EBITDA for Full Year 2023

SS&C Technologies announced its Q4 and full year 2023 financial results, highlighting record adjusted revenue and adjusted consolidated EBITDA.

Summary

• SS&C Technologies reported a 5.5% increase in both GAAP and adjusted revenue for Q4 2023, reaching $1,411.6 million and $1,412.3 million respectively.
• The company's GAAP diluted earnings per share decreased by 4.9% to $0.77, while adjusted diluted earnings per share increased by 8.6% to $1.26 for the quarter.
• For the full year 2023, GAAP revenue grew by 4.2% to $5,502.8 million, and adjusted revenue increased by 4.1% to $5,505.8 million.
• SS&C generated $1,215.1 million in net cash from operating activities for the year, a 7.1% increase compared to 2022.
• The company repurchased 2.4 million shares for $130.7 million in Q4 2023, at an average price of $54.74 per share.
• SS&C paid down $150.2 million in debt during the quarter, bringing the net leverage ratio to 3.05 times consolidated EBITDA.
• The company's adjusted consolidated EBITDA for Q4 2023 was a record $562.5 million, up 8.5% year-over-year.
• SS&C provided guidance for Q1 2024, projecting adjusted revenue between $1,396.7 million and $1,436.7 million and adjusted diluted earnings per share between $1.19 and $1.25.
• For the full year 2024, SS&C anticipates adjusted revenue between $5,667.7 million and $5,867.7 million and adjusted diluted earnings per share between $4.85 and $5.15.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record adjusted revenue and EBITDA, strong cash flow, and debt reduction. While there are some negative points, the overall tone is optimistic and indicates a healthy financial position.

Positives

• SS&C experienced strong growth in adjusted revenue and adjusted EBITDA.
• The company generated significant cash flow from operations.
• SS&C actively returned capital to shareholders through share repurchases and dividends.
• The company successfully reduced its debt and improved its leverage ratio.
• SS&C's DomaniRx venture launched successfully on January 1, 2024, opening up opportunities in healthcare.
• The company anticipates market conditions to strengthen in the financial services industry.

Negatives

• GAAP diluted earnings per share decreased by 4.9% in Q4 2023.
• GAAP net income attributable to SS&C decreased by 6.3% in Q4 2023.
• The company's healthcare business experienced a decline in organic revenue growth.
• The I&IM business segment experienced a significant decline in organic revenue growth.

Risks

• The company's performance is subject to the state of the economy and the financial services industry.
• SS&C's ability to realize anticipated benefits from acquisitions is a risk.
• Customer consolidation could impact demand for the company's products and services.
• The company's increasing focus on the hedge fund industry exposes it to market volatility.
• SS&C faces competition in its product and service offerings.
• The company is exposed to litigation and other claims.
• Disruptions, attacks, or failures affecting the company's software-enabled services pose a risk.
• SS&C's foreign operations are subject to various risks.
• The company faces privacy concerns related to the collection and storage of personal information.
• Evolving regulations and increased scrutiny from regulators are a risk.
• The company's ability to protect intellectual property assets is a concern.
• Delays in product development could impact the company's performance.
• The company's substantial indebtedness poses a risk.
• The market price of the company's stock is subject to fluctuations.

Future Outlook

SS&C anticipates market conditions to strengthen in the financial services industry and expects continued growth in healthcare with the launch of DomaniRx. The company provided guidance for Q1 and full year 2024, projecting growth in adjusted revenue and adjusted diluted earnings per share.

Management Comments

• SS&C exited 2023 with record adjusted revenue and record adjusted consolidated EBITDA, and we believe we have momentum to start the year, says Bill Stone, Chairman and Chief Executive Officer.
• We are seeing opportunities across the financial services industry, and anticipate market conditions to strengthen.
• And with DomaniRX successfully launching on January 1, 2024, we are seeing opportunities in healthcare.

Industry Context

SS&C's results reflect the ongoing demand for software and services in the financial and healthcare sectors. The company's focus on adjusted metrics highlights the importance of non-GAAP measures in evaluating performance in the technology industry. The launch of DomaniRx indicates a strategic move to expand into the healthcare market.

Comparison to Industry Standards

• SS&C's adjusted revenue growth of 5.5% in Q4 2023 is comparable to other established financial technology companies, such as Fiserv and Fidelity National Information Services (FIS), which have also reported mid-single-digit revenue growth in recent quarters.
• The adjusted EBITDA margin of 39.8% is strong and indicates efficient operations, placing SS&C in the upper tier of profitability compared to peers like Broadridge Financial Solutions, which typically have EBITDA margins in the 20-30% range.
• The company's focus on share repurchases and debt reduction is a common strategy among mature tech companies, similar to actions taken by companies like Oracle and IBM.
• SS&C's expansion into healthcare with DomaniRx is a strategic move similar to other tech companies diversifying into new sectors to drive growth, such as Salesforce's expansion into various cloud services.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance, share repurchases, and dividends.
• Employees may see opportunities for growth and development within the company.
• Customers will continue to receive software and services from SS&C.
• Suppliers and creditors will benefit from the company's financial stability.

Next Steps

• SS&C will hold an earnings call on February 13, 2024, to discuss the results and 2024 guidance.
• The company will continue to focus on organic growth and strategic acquisitions.
• SS&C will monitor market conditions and adjust its strategies as needed.

Key Dates

Keywords

Financial Software, Investment Management, Healthcare Software, SaaS, EBITDA, Revenue Growth, Earnings Per Share, Debt Reduction, Share Repurchase, Operating Cash Flow